This article provides a brief description of the mechanism of action of drugs commonly used in the treatment of nasal disorders. These include oral and topical vasoconstrictors, antihistamines, atropine-like drugs, cocaine, topical corticosteroids, and mast-cell stabilizers.
HavasTEColePHaightJ. Short term effects of topical sympathomimetic amines on the nasal mucosa; a functional evaluation. J Otolaryngol Soc Aust1988; 6: 129–30.
11.
InselPATermanBISlivkaSR. Molecular mechanisms and regulation of alpha-1 adrenergic receptors. In: RandMJRoperC, eds. Pharmacology, New York: Elsevier Science Publ, 1987: 13–6.
DeBernardisJFWinnMKerkmanDJKynclJJBucknerSHorromB. A new nasal decongestant, A-57219: A comparison with oxymetazoline. J Pharm Pharmacol1987; 39: 760–3.
14.
JacksonRTTurnerJS. An objective evaluation of xylometazoline in chronic sinusitis. EENT Monthly1967; 46: 1129–33.
15.
KalinerMEgglessonPAMathewsKP. Rhinitis and asthma. JAMA1987; 258: 2851–73.
16.
SchwartzJ-CBarbinGDucheminAM, Histamine receptors in the brain and their possible functions. In: GanelinCRParsonsME, eds. Pharmacology of histamine receptors. Bristol: Wright-PSG, 1982: 381.
17.
RichardsDMBrogdenRNHeelRCSpeightTMAveryGS. Astemizole, a review of its pharmacodynamic properties and therapeutic efficacy. Drugs1984; 28: 38–61.
18.
JacksonRTTeichgraeberJ. Low-dose topical atropine for rhinorrhea. Arch Otolaryngol1981; 107: 288–9.
19.
BorumP. Intranasal ipratropium: Inhibition of methacholine-induced hypersecretion. Rhinology1978; 16: 225–33.
20.
DolovichJMukherjeeJSalvatoriVA. Intranasal ipratropium bromide to control the hypersecretion of vasomotor rhinitis: A dose-response study. Am J Rhinol1989; 3: 221–4.
LydiattWMHuerterJVNancePNYonkersAJMooreGF. A prospective double-blind evaluation of cocaine, phenylephrine with xylocaine, and oxymetazoline with xylocaine for topical intranasal use. Am J Rhinol1989; 3: 105–12.
LipsFJO'ReillyJCloseDBeaumontGDClaphamM. The effects of formulation and addition of adrenaline to cocaine for haemostasis in intranasal surgery. Anaesth Intensive Care1987; 15: 141–6.
25.
HerseySJJacksonRT. Cocaine uptake by nasal mucosa in vitro. Abstracts of 13th Meeting, Feb 4–8, 1990. St. Petersburg Beach, Ha.: Assoc Res Otolaryngol, 1990: 283.
BrownMSPetersSPAdkinsonNF, Arachidonic acid metabolites during nasal challenge. Arch Otolaryngol Head Neck Surg1987; 113: 179–83.
28.
JungTTKJuhnSKHwangDStewartR. Prostaglandins, leukotrienes, and other arachidonic acid metabolites in nasal polyps and nasal mucosa. Laryngoscope1987; 97: 184–9.
29.
PipkornUProudDLichtensteinLMKagey-SobotkaANormanPSNaclerioRM. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med1987; 316: 1506–10.
30.
MazurekNSchindlerHSchurholzThPechtI. The cromolyn binding protein constitutes the calcium channel of basophils opening upon immunological stimulus. Proc Natl Acad Sci1984; 81: 6841–5.
31.
KayABWalshGMMoqbelR, Disodium cromoglycate inhibits activation of human inflammatory cells in vitro. J Allergy Clin Immunol1987; 80: 1–8.
32.
ChurchMK. Reassessment of mast cell stabilizers in the treatment of respiratory disease. Ann Allergy1989; 62: 215–21.
